Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting
This prospective, open-label, multicenter, observational study will investigate the effectiveness and safety of MabThera SC (rituximab, subcutaneous) induction therapy in patients with non-Hodgkin's lymphoma, following a first initial treatment of MabThera IV (rituximab, intraveneous). Induction treatment period in the study is estimated to be 8 months.
Non-Hodgkin's Lymphoma
Response rate using the International Working Group criteria, 8 months
Incidence of adverse events, Through to end of study, up to approximately 1 year|Incidence of administration related reactions during induction therapy in patients who have previously received at least one dose of MabThera IV, Through to end of study, up to approximately 1 year|Incidence of serious adverse events, Through to end of study, up to approximately 1 year
This prospective, open-label, multicenter, observational study will investigate the effectiveness and safety of MabThera SC (rituximab, subcutaneous) induction therapy in patients with non-Hodgkin's lymphoma, following a first initial treatment of MabThera IV (rituximab, intraveneous). Induction treatment period in the study is estimated to be 8 months.